Inclusion Criteria:

          1. Signed Informed Consent.

          2. Age ≥ 18 years.

          3. Part 1: Patients with histologically confirmed relapsed or refractory B-cell
             malignancies, including Grades 1-3a FL, MZL, MCL, and CLL/SLL.

             Part 2: Patients with histologically confirmed B-cell malignancies including r/r FL,
             r/r MZL and CLL/SLL with/without prior treatment.

          4. Life expectancy (in the opinion of the investigator) of ≥ 4 months.

          5. ECOG performance status of 0 ~1.

          6. Must have adequate organ function.

          7. Negative test results for HBV ([HBsAg (-)] and non-active HBV or HCV infection

        Exclusion Criteria:

          1. Pregnant or breast-feeding or intending to become pregnant during the study.

          2. Prior treatment with systemic immunotherapeutic agents.

          3. Known allergies to Orelabrutinib (ICP-022) or its excipients or infection with HIV.

          4. Treatment with any chemotherapeutic agent, or any other investigational therapies
             within 4 weeks prior to first dose of the study drug.

          5. History of allogeneic stem-cell (or other organ) transplantation or confirmed
             progressive PML.

          6. Any external beam radiation therapy within 6 weeks prior to the first dose of the
             study drug.

          7. Concurrent use of warfarin or other vitamin K antagonists or anticoagulation therapies
             or strong CYP3A inhibitor.

          8. Active uncontrolled infections.

          9. Recent infection requiring IV anti-infective treatment that was completed ≤ 14 days
             before the first dose of study drug.

         10. Unresolved toxicities from prior anti-cancer therapy.

         11. Medically apparent CNS lymphoma or leptomeningeal disease.

         12. Current or previous history of CNS disease.

         13. Major surgery or significant traumatic injury < 28 days prior to the first dose of the
             study drug.

         14. Patients with another invasive malignancy in the last 2 years.

         15. Significant cardiovascular disease or active pulmonary disease.

         16. Received systemic immunosuppressive medications.